1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,489 | 0,521 | 12.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Cereno Scientific AB: Cereno Scientific Enters Collaboration with PHA Europe & Global to Advance Patient-centered Drug Development in Pulmonary Hypertension | 356 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced a collaboration... ► Artikel lesen | |
| 10.04. | Cereno Scientific to Participate at Nordic Health Summit Japan and ChinaBio Partnering Forum 2026 | 1 | Cision News | ||
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 04.04. | Cereno Scientific AB: Cereno Scientific Highlights Strategic Value of Meeting Primary Endpoint of Safety and Tolerability of 12-month CS1 Data in PAH | 794 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today provides additional... ► Artikel lesen | |
| 31.03. | Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program | 329 | PR Newswire | GOTHENBURG, Sweden, March 31, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 27.03. | Cereno Scientific: Stifel Initiates Coverage with Buy Rating and Price Target of SEK 20 | 1 | Cision News | ||
| 23.03. | Cereno Scientific - Inflection points coming into view | 364 | Edison Investment Research | Cereno Scientific's FY25 results mark a strategically productive period, with multiple value inflection points coming into focus in FY26. With the Phase IIb start for lead asset CS1 expected in Q226... ► Artikel lesen | |
| 19.03. | Cereno Scientific - capital markets day highlights (Video) | 356 | Edison Investment Research | In this video, we go behind the scenes at Cereno Scientific's capital markets day, speaking with key stakeholders, including company leadership, industry experts and patients living with pulmonary arterial... ► Artikel lesen | |
| 17.03. | Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD | 1.190 | PR Newswire | GOTHENBURG, Sweden, March 17, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 27.02. | Cereno Scientific AB: Cereno Scientific Publishes Year-end Report for 2025 (January 1 - December 31, 2025) | 809 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 20.02. | Cereno Scientific - CMD reaffirms shifting focus to clinical delivery | 424 | Edison Investment Research | Cereno Scientific's recent capital markets day (CMD) centered on CS1's progression from early clinical validation into Phase IIb development, a key inflection for the investment thesis. Supported by... ► Artikel lesen | |
| 04.02. | Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease | 600 | PR Newswire | GOTHENBURG, Sweden, Feb. 4, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 04.02. | Cereno Scientific AB: Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease | 579 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 03.02. | Cereno Scientific AB: Cereno Scientific Provides Update on Expanded Access Program for CS1 - initial learnings expected in Q1 2026 | 354 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the... ► Artikel lesen | |
| 02.02. | Cereno Scientific Announces Program and Speakers for the Capital Markets Day on February 5, 2026 | 1 | Cision News | ||
| 28.01. | Cereno Scientific to Present CS014 Data and Participate in Panel at Scientific Conference PVRI 2026 Dublin | 1 | Cision News | ||
| 14.01. | Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases | 356 | PR Newswire | GOTHENBURG, Sweden, Jan. 14, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 12.01. | Cereno Scientific - Entering a value inflection phase | 458 | Edison Investment Research | We refresh our investment case for Cereno Scientific as the company enters a key value inflection period, with its lead asset CS1 expected to initiate a Phase IIb study in Q226, followed by Phase II... ► Artikel lesen | |
| 08.01. | Cereno Scientific AB: Cereno Scientific Receives approximately SEK 5 million Through Exercise of 728,957 Warrants by Arena Investors, LP | 420 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B) ("the Company"), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announces... ► Artikel lesen | |
| 18.12.25 | Cereno Scientific's Board of Directors and Management Enter Lock-up Agreements | 2 | Cision News | ||
| 18.12.25 | Cereno Scientific to Host Capital Markets Day on February 5, 2026 | 2 | Cision News |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,800 | +2,27 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 109,03 | +0,35 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| ERNEXA THERAPEUTICS | 12,150 | +1,17 % | Ernexa Therapeutics Inc.: Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 343,62 | +0,12 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| MODERNA | 45,405 | +0,09 % | Moderna: Hantavirus-Schlagzeilen treiben Impfstoff-Aktie an | Das Hantavirus ist auf einem kleinen Kreuzfahrtschiff im Atlantik ausgebrochen. Die Weltgesundheitsorganisation (WHO) hat inzwischen fünf von acht Verdachtsfällen als offizielle Fälle bestätigt. Aus... ► Artikel lesen | |
| CG ONCOLOGY | 72,05 | -0,03 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,400 | -0,12 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 16,140 | -0,06 % | CGEM Forum Reveals Only 6,000 Moroccan Firms Export, a Path to Change chartered | ||
| ARCUTIS BIOTHERAPEUTICS | 20,700 | +0,05 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| BIONTECH | 79,70 | -0,13 % | Alarm bei BioNTech! Milliarden bei Hensoldt! Kaufchance bei North Arrow Minerals! | "Erst kaufen, dann killen", so reagierte Tübingens Oberbürgermeister Boris Palmer auf die geplanten Standortschließungen von BioNTech. Denn in diesem Rahmen sollen praktisch alle Standorte der erst... ► Artikel lesen | |
| ERASCA | 10,390 | +0,10 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| EVOTEC | 5,080 | -2,31 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik | EQS-News: Evotec SE
/ Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung
Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik... ► Artikel lesen | |
| NUVALENT | 102,64 | +0,10 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,960 | +0,05 % | H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk | ||
| COGENT BIOSCIENCES | 34,530 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress |
CERENO SCIENTIFIC AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -7,49 % bei einem Aktienkurs von 0,495 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.